Paul L Hallenbeck

Title: Paul L Hallenbeck: Innovator in Oncolytic Therapy

Introduction

Paul L Hallenbeck is a notable inventor based in Blue Bell, PA (US). He has made significant contributions to the field of cancer treatment through his innovative research and patents. His work primarily focuses on the use of oncolytic viruses in therapeutic applications.

Latest Patents

Hallenbeck holds a patent for "Second generation Seneca Valley virus oncolytic therapy: compositions and methods thereof." This patent describes compositions and methods utilizing the Seneca Valley Virus (SVV) or its derivatives, combined with an interferon type I (IFN-I) inhibiting agent, specifically an mTOR inhibitor, for treating cancer in subjects. The methods disclosed in the patent emphasize the importance of the expression levels of ANTXR1 and IFN-I in the cancer of the subject. Additionally, the patent outlines methods for predicting the efficacy of SVV treatment in conjunction with IFN-I inhibiting agents.

Career Highlights

Throughout his career, Hallenbeck has worked with prominent organizations, including Seneca Therapeutics, Inc. and Columbia University. His experience in these institutions has allowed him to advance his research and contribute to the development of innovative cancer therapies.

Collaborations

Hallenbeck has collaborated with notable colleagues in his field, including Vincent Racaniello and Amy B Rosenfeld. These collaborations have further enriched his research and expanded the impact of his work in oncolytic therapy.

Conclusion

Paul L Hallenbeck is a distinguished inventor whose work in oncolytic therapy has the potential to transform cancer treatment. His innovative approaches and collaborations highlight his commitment to advancing medical science.